Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GRI Bio ( (GRI) ) has shared an announcement.
On June 26, 2025, GRI Bio announced positive interim safety results from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis, showing the drug to be safe and well-tolerated in the first 24 patients. The Independent Data Monitoring Committee recommended the study continue, as no safety concerns were found, reinforcing GRI Bio’s position in developing novel treatments for fibrotic diseases.
The most recent analyst rating on (GRI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases. The company is advancing a pipeline of Natural Killer T (NKT) cell modulators, with its lead program, GRI-0621, targeting idiopathic pulmonary fibrosis, a disease with significant unmet medical needs.
Average Trading Volume: 521,234
Technical Sentiment Signal: Sell
Current Market Cap: $3.17M
For an in-depth examination of GRI stock, go to TipRanks’ Overview page.